For research use only. Not for therapeutic Use.
SBC-115337, as a potent benzofuran compound, is a PCSK9 inhibitor with an IC50 value of 0.5 μM[1][2].
The potent compound (SBC-115,337) shows an IC50 of 0.6 μM measured in an in vitro ELISA assay to monitor the effect of PCSK9 binding to the recombinant LDLR. SBC-115,337 at 1.2 μM induces more than tenfold upregulation of LDLR in HepG2 cells with respect to the control, increases uptake of fluorescently labeled DiI-LDL and loweres LDL-c levels in mice fed a high-fat diet[2].
| Catalog Number | I045245 |
| CAS Number | 423148-46-3 |
| Synonyms | N-[4-[[4-(1,3-benzoxazol-2-yl)phenyl]carbamoyl]phenyl]-1-benzofuran-2-carboxamide |
| Molecular Formula | C29H19N3O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C29H19N3O4/c33-27(30-21-15-11-19(12-16-21)29-32-23-6-2-4-8-25(23)36-29)18-9-13-22(14-10-18)31-28(34)26-17-20-5-1-3-7-24(20)35-26/h1-17H,(H,30,33)(H,31,34) |
| InChIKey | ALQIZRCPSILFNQ-UHFFFAOYSA-N |
| SMILES | C1=CC=C2C(=C1)C=C(O2)C(=O)NC3=CC=C(C=C3)C(=O)NC4=CC=C(C=C4)C5=NC6=CC=CC=C6O5 |
| Reference | [1]. Xu S, et al. Small molecules as inhibitors of PCSK9: Current status and future challenges. Eur J Med Chem. 2019;162:212-233. [2]. Lavecchia A, et al. Recent advances in developing PCSK9 inhibitors for lipid-lowering therapy. Future Med Chem. 2019;11(5):423-441. |
